Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART

MLA

John W. Mellors, et al. “Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.” Open Forum Infectious Diseases, vol. 5, Oct. 2018. EBSCOhost, https://doi.org/10.1093/ofid/ofy242.

APA

John W. Mellors, Julie E. Ledgerwood, Richard A. Koup, Christine M. Durand, Michael C. Keefer, Susan L. Koletar, Lu Zheng, Justin Ritz, Joshua C. Cyktor, Bernard J.C. Macatangay, Robert T. Bailer, Joseph J. Eron, & Sharon A. Riddler. (2018). Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infectious Diseases, 5. https://doi.org/10.1093/ofid/ofy242

Chicago

John W. Mellors, Julie E. Ledgerwood, Richard A. Koup, Christine M. Durand, Michael C. Keefer, Susan L. Koletar, Lu Zheng, et al. 2018. “Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART.” Open Forum Infectious Diseases 5 (October). doi:10.1093/ofid/ofy242.